ページ4 - 最高の化学療法医師 - トップ156名の医師

この医師は小児血液学および腫瘍学の分野での第一人者であり、特に小児の血液疾患および骨癌（肉腫）に特化しています。現在、この医師はテルアビブのSourasky Medical Centerの小児血液腫瘍科のディレクターを務め、Dana Children's Hospitalの上級小児科医でもあります。この医師は骨癌および軟部組織肉腫の治療を調整し、血液凝固障害を管理し、早産児の血液学を監督しています。この医師はイスラエル小児血液腫瘍学会（ISPHO）のメンバーです。

この医師はベングリオン大学を卒業し、Kaplan Medical Centerで小児医学を専門とし、Schneider Children's Medical Centerで小児血液学および腫瘍学をさらに専門としました。追加のトレーニングはイタリアのRizzoli Orthopaedic Instituteで骨および軟部組織の腫瘍学において完了しました。

メフメット・ファイク・チェティンダğ博士は、30年以上にわたる実践を経て、腫瘍学の分野で専門家としての地位を確立しています。特に、頭頸部癌に焦点を当てた彼の広範な研究と多数の出版物は、この分野に大きな貢献をしています。彼は化学療法、放射線療法、前立腺除去術などの多様な手技を実行する技能を持っています。

教育

• 1984年にハジェッテペ大学で医学の学位を取得しました。
• 1990年にアンカラ訓練研究病院で放射線腫瘍学を専攻。

プロフェッショナルキャリア

• 1990年から1991年にかけて、アンカラ・ヌムネ訓練調査病院に勤務しました。
• 1993年から2009年にかけて、ドクター・アブドゥラフマン・ユルタスラン腫瘍学訓練調査病院で働きました。
• 2010年から2016年にかけて、アンカラ・アタテュルク訓練研究病院のチームに属していました。

出版物と研究

• 国内科学会議で71件、国際科学会議で14件の論文を発表しました。
• 国内雑誌で6件、国際雑誌で22件の記事を執筆。
• 書籍の一章を執筆し、査読付きの出版物が2件あります。

ウィーン大学教授のウォルター・クレペトコ博士は、オーストリアで最も著名な胸部外科医の一人であり、肺移植と胸部腫瘍学における先駆的な業績により国際的に認められています。彼のキャリアは数十年にわたり、臨床における卓越性、学術的リーダーシップ、革新的な技術を組み合わせ、ウィーンを進んだ肺外科の国際センターにしています。

彼は1970年代にウィーン大学で医学を学び、卒業後に外科の訓練を始めました。彼は早いうちに胸部および心血管外科を専門としており、難治性の肺疾患の治療に重点を置いています。彼のキャリアは、外科手術と研究を組み合わせることで急速に進展し、肺移植における主要な革新に貢献しました。

     1980年代 – ウィーン総合病院（AKH）にて胸部外科の専門家研修を修了。

     1989年 – オーストリアで初めての肺移植を行い、ウィーンをこの分野のパイオニアとして確立。

     1990年代から2000年代 – AKHウィーンの肺移植プログラムを開発・拡大し、ヨーロッパの主要なセンターの一つとなる。

     2000年代 – ウィーン医科大学胸部外科部門の部門長に就任し、臨床実践、研究、および将来の外科医の訓練を監督。

     2010年代 – 胸部腫瘍学、低侵襲胸部外科、新しい移植医学アプローチにおける革新で国際的に認められる。

     現在 – ウィーンで主導的なコンサルタントおよび教授として働き続け、複雑な胸部疾患の治療、肺移植の手術を行い、肺外科における国際的なコラボレーションを促進しています。

クレペトコ教授は、特にそのチームが数々の重要な手術を実施してきた肺移植での功績で高く評価されており、オーストリアのF1レーサー、ニキ・ラウダの肺移植も含まれます。彼の胸部外科の進歩に対する努力は無数の命を救い、新世代の外科医にインスピレーションを与えてきました。彼は世界クラスの外科スキルを学術的な指導と組み合わせ、オーストリアの国際医学における評判に大きく貢献しています。

Univ. Prof. Dr. ウォルフガング・ケストラーは、オーストリアの著名な医学的腫瘍学者および内科医であり、乳がん、婦人科悪性腫瘍、および標的がん治療の専門知識で国際的に認められています。臨床、学術、研究の経験が20年以上にわたり、彼はオーストリアにおける個別化がん治療の最前線の権威の一人となりました。

彼はウィーン大学で医学を学び、1990年代に卒業し、その後ウィーン医科大学で内科および医学的腫瘍学のレジデンシーを修了しました。キャリアの初期には、彼は先進的な腫瘍学者と共に標的療法と個別化医療の開発に従事し、これは後の彼の多くの研究に影響を与える分野となりました。

   1990年代 – ウィーン総合病院（AKH）での内科および腫瘍学の研究およびレジデンシーを修了しました。

   2000年代 – 固形腫瘍腫瘍学に特化し、乳がんや婦人科がんに焦点を当て、標的療法に関する初期の臨床試験に貢献しました。

   2010年代 – ウィーン医科大学の准教授および腫瘍学の臨床部門の副主任に任命され、分子腫瘍学の推進に貢献しました。

   現在 – ウィーン私立クリニックで上級コンサルタントとして勤務し、ウィーン医科大学での学術活動を続け、個別化された全身がん治療、免疫療法、および転位がん研究に注力しています。

ケストラー教授の研究関心には、バイオマーカーの開発、腫瘍生物学、および標的薬剤への耐性メカニズムが含まれており、正確な腫瘍学における新しい治療戦略の設計に貢献しています。彼の科学研究は主要な国際雑誌に掲載されており、彼はヨーロッパの腫瘍学ネットワークに積極的に参加し続けています。

診断の正確さ、臨床的共感、革新的な考え方で知られるケストラー教授は、科学的進歩と慈悲深い患者ケアを組み合わせた個別化がん医学の未来を体現しています。

Dr. Christiane Thallinger is an Austrian dermatologist and venereologist. She focuses on skin cancer and oncologic dermatology. She began her medical career in 1999. She completed dermatology training at the Medical University of Vienna. She later served as a senior physician in its Department of Dermatology.

Her expertise includes diagnosis and treatment of melanoma, basal cell carcinoma, and squamous cell carcinoma. She performs dermatosurgery, cryotherapy, and photodynamic therapy. She also manages skin side effects caused by cancer treatment.

She is active in patient care and academic research. She is recognized for her patient-centered approach and for advancing dermatologic oncology in Austria.

アミール博士は、乳がんに対する様々な療法、例えば化学療法、放射線療法、ホルモン療法、及びKeytruda（ペンブロリズマブ）を用いた標的療法を専門としています。彼の学術的な貢献には、国内および国際的な科学会議での30を超えるプレゼンテーションが含まれています。

受賞歴

• 2004年：博士課程学生向けウルフ賞
• 2006年：MD/PhD学生向けフォークス賞
• 2013年：ESMO乳がんトランスレーショナルリサーチ賞
• 2016年：ISCORT年のベストペーパー賞
• 2017年：ISCORT年のベストペーパー賞

所属

• イスラエル医師会
• イスラエル臨床腫瘍学会
• イスラエル癌研究協会（ISCR）
• 欧州がん研究協会（EACR）
• 欧州臨床腫瘍学会（ESMO）

学歴

• 1998-2007年：ヘブライ大学、イスラエル、エルサレム（MD/PhDコース）
• 2013-2015年：ESMO乳がんトランスレーショナルとクリニカルリサーチフェローシップ、ジュール・ボルデ研究所、ブリュッセル
• 2012年：乳がん研究フェローシップ、エモリー大学国際プログラム、アトランタ、GA、米国

Pediatric Hematology and Oncology / Pediatric Oncology

盧佩華博士は、米国および中国の両国でライセンスを取得した血液腫瘍内科の専門家であり、細胞免疫療法の先駆者です。北京医科大学を卒業後、米国で研鑽を積み、スタンフォード大学にて臨床フェローシップを修了、その後、米国国立衛生研究所（NIH）より二つの権威ある賞を受賞しました。中国における腫瘍浸潤リンパ球（CIK）細胞療法の最初の導入者の一人でもあります。2015年に帰国後は、CAR-T療法および血液がん治療の発展を牽引してきました。盧博士は、中国非公立医療機関協会血液病委員会委員長を含む10以上の医療関連組織において指導的役割を担っています。また、「医療管理賞」や「年間最優秀人民医師」など、国家レベルの表彰も受けています。
 

診療科：血液内科・リンパ腫＆骨髄腫センター

この医師は、乳がん、肺がん、消化器系がんの治療を専門とする腫瘍学者です。現在、医師はIstinye Liv University Hospitalで診療を行っています。<\/p>

多くの著名な機関でのキャリアを持ち、医師はMalatya State Hospitalで内科専門医として、Ankara Oncology Clinicで医師として、Erzurum Regional Training and Research Hospitalの腫瘍学部門のメンバーとして勤務してきました。<\/p>

医師はSelcuk Universityの医学部を卒業し、2016年に准教授の称号を取得しました。<\/p>

フォックス・ヴィオラ博士は、BKZゾーリンゲン血液腫瘍科・緩和医療科の主任医師です。同クリニックは、認定された集学的腫瘍センターです。フォックス博士は、ドイツおよびヨーロッパにおける腫瘍性疾患の薬物療法の第一人者であり、15年以上の臨床経験を有しています。

同博士は、ドイツ腫瘍学・血液腫瘍学会（GDHO）、ドイツ医師会、およびアメリカがん研究学会に所属しています。また、分子生物学の研究にも従事しており、その研究成果はがん治療および分子診断の発展に貢献しています。

主な専門領域は、化学療法、免疫療法、分子標的療法、および放射線療法です。フォックス博士は、革新的な治療法と患者への細やかな配慮で知られています。その取り組みにより、高い治癒率を達成し、同僚からの高い評価を得ています。

Associate Professor Dr. Yusuf AÇIKGÖZ
Specialization: Medical Oncology

Education:

• 2004-2011: İnönü University Faculty of Medicine
• 2011-2016: Ankara Numune Training and Research Hospital, Internal Medicine
• 2017-2022: Health Sciences University, Medical Oncology

Professional Experience:

• 2016-2017: Bingöl City Hospital, Internal Medicine
• 2021-2022: Health Sciences University, Medical Oncology
• 2022-2023: Kastamonu Education and Research Hospital, Medical Oncology
• 2023-2024: Ohio State University, Medical Oncology
• 2024-Present: Lokman Hekim University, Medical Oncology, Ankara Hospital

Clinical Trials, Courses, Certifications:

Clinical Trials:

• 2017-2021: Phase III, CheckMate-649 Study (Assistant Investigator)
• 2022-Present: Phase III, Fortitude-101 Study (Assistant Investigator)

Courses:

• 2018: Medicres Basic and Advanced Biostatistics Training Program (ongoing), Istanbul-Vienna
• 2019: Immuno-Oncology Education Course, March 1-2, 2019, Vienna, Central European Cooperative Oncology Group (CECOG)
• 2018: Good Clinical Practice Certification, April 7-8, 2018, Ankara, Health Sciences University
• 2017: Basic Oncology Training Program, November 25-26, 2017, Adana, Clinical Oncology Society
• 2016: Basic Ultrasonography Course (10 hours theoretical + 10 hours practical), September 24-25, 2016, Ankara, Turkish Emergency Medicine Association

Certifications:

• Ongoing: ECFMG Certification
• 2024: CITI Responsible Conduct of Research (The Ohio State University)
• 2024: CITI IACUC-Laboratory Animal Research (The Ohio State University)
• 2024: CITI Human Subjects Protection (The Ohio State University)
• 2024: CITI Good Clinical Practice (The Ohio State University)
• 2023: Occupational English Test (OET)
• 2019: International English Language Testing System (IELTS), Total Score: 6.5, May 26, 2019, Ankara, British Council
• 2017: USMLE Step 2 CK Exam; Score: 244, February 7, 2017
• 2016: USMLE Step 1 Exam; Score: 215, August 25, 2016

Memberships:

• American Society of Clinical Oncology (ASCO) - 2022
• Turkish Society of Medical Oncology - 2020

Séverine Iborra博士は、ゾーリンゲン市立病院の婦人科・産科部門を率いており、乳がん治療を中心とした婦人科腫瘍学を専門としています。

• 婦人科腫瘍学および特殊産科学の認定資格を有する
• ロボット手術を含む低侵襲技術に精通している
• ドイツの主要な婦人科学会の活動的なメンバーである
• 分子腫瘍学研究において多数の論文を発表している

Education & Expertise

• 1997 | Hacettepe University Faculty of Medicine – Medical Degree
• 2003 | Uludağ University Faculty of Medicine – Internal Medicine Specialization
• 2007 | Uludağ University Faculty of Medicine – Hematology Subspecialty

Professional Experience

• 1998 (May – September) | Practitioner, Dr. Salaha Health Center, Rize
• 1998 to 2003 | Research Assistant, Uludağ University Faculty of Medicine, Internal Medicine Department
• 2003 to 2007 | Hematology Subspecialist, Uludağ University Faculty of Medicine, Hematology Division
• 2007 to 2011 | Hematology Specialist, Bursa Ali Osman Sönmez Oncology Hospital (Compulsory Service)
• 2011 to 2013 | Hematology Specialist, Private Anadolu Health Center Bone Marrow Transplant Center, Gebze
• 2014 to 2015 | Assistant Professor, Yeditepe University Faculty of Medicine, Department of Internal Medicine
• 2015 to 2020 | Associate Professor, Yeditepe University Faculty of Medicine, Department of Internal Medicine
• 2020 to Present | Professor, Yeditepe University Faculty of Medicine, Department of Internal Medicine

Courses & Certifications

• Autologous and Allogeneic Stem Cell Transplantation Certificate
• Clinical Phytotherapy Application Certificate
• Flow Cytometry Experience Certificate
• EBMT Stem Cell Transplantation Course

Professional Memberships

• Turkish Medical Chamber
• Turkish Hematology Association (Full Member, No: 893)
• Turkish Therapeutic Apheresis Association (Current President)
• Geriatric Hematology Association
• Hematological Oncology Association
• EBMT (European Bone Marrow Transplantation)

Awards & Recognitions

• 2011 | 6th Turkish Therapeutic Apheresis Congress – Young Researcher Award

Education & Expertise

• 1998 to 2004 – Istanbul University, Istanbul Faculty of Medicine
• 2005 to 2009 – Düzce University, Internal Medicine Specialization
• 2009 to 2010 – Beytüşşebap State Hospital, Compulsory Internal Medicine Service
• 2010 to 2013 – Bülent Ecevit University, Medical Oncology Specialization
• 2013 to 2015 – Recep Tayyip Erdoğan University, Medical Oncology Compulsory Service
• 2015 to Present – Associate Professor, Recep Tayyip Erdoğan University
• 2015 to 2021 – Lecturer, Medical Oncology, Sakarya University Faculty of Medicine
• 2020 to Present – Professor, Sakarya University Faculty of Medicine
• 2020 to Present – Ph.D. Student, Inorganic Chemistry, Sakarya University

Experience

• 2008 – Cleveland Clinic, Rheumatology & Gastroenterology Rotation
• 2016 to 2017 – Northeastern University, The Center for Pharmaceutical Biotechnology and Nanomedicine, Boston, U.S.

Professional Memberships

• TTOD (Turkish Society of Medical Oncology)
• ASCO (American Society of Clinical Oncology)
• ESMO (European Society for Medical Oncology)

Diseases

• Lung Cancer
• Skin Cancers
• Gastrointestinal Cancers
• Genitourinary Cancers
• Gynecological Cancers
• Colon Cancer
• Breast Cancer
• Rare Cancers

Treatment Methods

• Individual Treatments (Comprehensive Genomic Profiling)
• Targeted Therapies
• Immunotherapy
• Cancer Vaccines
• Chemotherapy
• Clinical Research/Experimental Medical Research

Experience

• 2017- 2024: Katip Çelebi University Faculty of Medicine Atatürk Education and Research Hospital Medical Oncology Clinic Associate Professor / Lecturer
• 2022 December – 2023 March: Academic visitor Moffitt Cancer Center Cutaenous Oncology Clinic Tampa, Florida USA
• 2013- 2017: Katip Çelebi University Faculty of Medicine Atatürk Training and Research Hospital – Medical Oncology Clinic Specialist Physician
• 2012-2013: Izmir Education and Research Hospital, Medical Oncology Specialist Physician
• 2012-2012: Mersin State Hospital, Medical Oncology Specialist Physician
• 2010-2012: Dokuz Eylül University Faculty of Medicine, Department of Medical Oncology, Sub-branch Research Assistant
• June-August 2008, December 2008 – February 2009: Memorial Sloan Kettering Cancer Center Observership programme
• 2007-2009: Kartal Education and Research Hospital, Medical Oncology Sub-branch Research Assistant
• 2006-2007: Siirt State Hospital, Internal Medicine, Specialist Physician
• 2005-2006: Çukurova University Faculty of Medicine, Medical Oncology Sub-branch Research Assistant
• 2004-2005: SSK Siirt Hospital, Internal Medicine Specialist Physician
• 2003-2004: SSK Mardin Hospital, Internal Medicine Specialist Physician
• 1998-2003: SSK Izmir Training and Research Hospital, 3rd Internal Medicine Clinic, Research Assistant
• 1998-1998: SSK Izmir Training and Research Hospital Infectious Diseases Research Assistant
• 1997-1998: Izmir Ataturk Training and Research Hospital, Anesthesiology and Reanimation Clinic, Research Assistant
• 1995-1997: Şırnak Cizre Central Health Center
• 1994-1995: Şırnak İdil Oyalı Village Health Center

Professional Memberships

• Turkish Society of Medical Oncology 2008 
• (2018-2021 Term Board Member)
• Izmir Oncology Group, Board Member (2014 -…)
• Geriatric Oncology Association, Board Member (2015-…)
• Mediterranean Oncology Association Board Member (2020 -…)
• Turkish Biochemistry Association, Member, 2016
• European Society of Medical Oncology, Member, 2012
• American Society of Clinical Oncology, Member, 2008

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Dr. Eckhart Weidemann is one of best non hodgkin lymphoma doctors. He heads the Hematology sector of Nordwest Clinic specializing in blood disorder treatment. The professor has over 30 years of practice.

Dr. Ercan Ozden is a specialist in internal medicine and medical oncology. He earned his medical degree and completed his residency at Istanbul University, Cerrahpaşa Faculty of Medicine. He later received a subspecialty in medical oncology at Kocaeli University Faculty of Medicine from 2016 to 2020.

Dr. Ozden has worked in medical oncology at Şırnak State Hospital. He has also served as an internal medicine specialist at Bağcılar Private Safa Hospital and Küçükçekmece Batı Bahat Hospital. He has extensive clinical experience in both internal medicine and oncology.